Evaluations of healthcare interventions, e.g. new drugs or other new treatment strategies, commonly include a cost-effectiveness analysis (CEA) that is based on the application of health economic (HE) models. As end users, patients are important stakeholders regarding the outcomes of CEAs, yet their knowledge of HE model development and application, or their involvement therein, is absent. This paper considers possible benefits and risks of patient involvement in HE model development and application for modellers and patients. An exploratory review of the literature has been performed on stakeholder-involved modelling in various disciplines. In addition, Dutch patient experts have been interviewed about their experience in, and opinion about, the application of HE models. Patients have little to no knowledge of HE models and are seldom involved in HE model development and application. Benefits of becoming involved would include a greater understanding and possible acceptance by patients of HE model application, improved model validation, and a more direct infusion of patient expertise. Risks would include patient bias and increased costs of modelling. Patient involvement in HE modelling seems to carry several benefits as well as risks. We claim that the benefits may outweigh the risks and that patients should become involved.

Additional Metadata
Persistent URL dx.doi.org/10.1007/s40258-015-0200-7, hdl.handle.net/1765/89161
Journal Applied Health Economics and Health Policy
Citation
van Voorn, G.A.K, Vemer, P, Hamerlijnck, D, Corro Ramos, I, Teunissen, G.J, Al, M.J, & Feenstra, T.L. (2016). The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling. Applied Health Economics and Health Policy, 14(2), 129–133. doi:10.1007/s40258-015-0200-7